NCT01183598View on ClinicalTrials.gov

A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Castleman's Disease
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

maintenance dose

Trial Locations (1)

72205-7199

Little Rock

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01183598 - A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment | Biotech Hunter | Biotech Hunter